Human monoclonal antibody 10-40 neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo, showing greater breadth than other RBD-directed antibodies.
Does the human monoclonal antibody 10-40 broadly neutralize sarbecoviruses and protect against SARS-CoV-2 and SARS-CoV in vivo?
The identification of the broadly neutralizing monoclonal antibody 10-40 and its conserved epitope cluster provides a promising agent for pandemic preparedness and pan-sarbecovirus vaccine development.
Abstract The devastation caused by SARS-CoV-2 has made clear the importance of pandemic preparedness. To address future zoonotic outbreaks due to related viruses in the sarbecovirus subgenus, we identified a human monoclonal antibody, 10-40, that neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo . Comparative studies with other receptor-binding domain (RBD)-directed antibodies showed 10-40 to have the greatest breadth against sarbecoviruses and thus its promise as an agent for pandemic preparedness. Moreover, structural analyses on 10-40 and similar antibodies not only defined an epitope cluster in the inner face of the RBD that is well conserved among sarbecoviruses, but also uncovered a new antibody class with a common CDRH3 motif. Our analyses also suggested that elicitation of this class of antibodies may not be overly difficult, an observation that bodes well for the development of a pan-sarbecovirus vaccine. One sentence summary A monoclonal antibody that neutralizes or binds all sarbecoviruses tested and represents a reproducible antibody class.
Liu et al. (Tue,) conducted a other in Sarbecovirus infection (SARS-CoV-2 and SARS-CoV). Human monoclonal antibody 10-40 vs. Other receptor-binding domain (RBD)-directed antibodies was evaluated on Neutralization or binding of sarbecoviruses in vitro and protection against SARS-CoV-2 and SARS-CoV in vivo. Human monoclonal antibody 10-40 neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo, showing greater breadth than other RBD-directed antibodies.